Id |
Subject |
Object |
Predicate |
Lexical cue |
T195 |
0-401 |
Sentence |
denotes |
During hospitalization, there were no important between-group differences in organ function damage, including acute liver injury (47 [62.7%] vs 37 [61.7%], P = 0.9052), hyperglycemia (33 [44.0%] vs 31 [51.7%], P = 0.3754), acute kidney injury (three [4.0%] vs 0 [0%], P = 0.3275), and acute cardiac injury (two [2.7%] vs one [1.7%], P = 0.8447) in the good-sleep group and poor-sleep group (Table 3 ). |
T196 |
402-609 |
Sentence |
denotes |
Patients in the poor-sleep group had an increased incidence of HAI (seven [9.3%] vs one [1.7%]) compared to those in the good-sleep group; however, this difference was not significant (P = 0.1316) (Table 3). |
T197 |
610-750 |
Sentence |
denotes |
One patient with HAI in the good-sleep group had pulmonary infection of extended-spectrum β-lactamase (EBSL)-positive klebsiella pneumoniae. |
T198 |
751-1267 |
Sentence |
denotes |
Meanwhile, HAI in the poor-sleep group included the following: two patients had pulmonary infection of carbapenem-resistant Acinetobacter Baumanii and Candida tropicalis, two patients had urinary tract infection, one patient had blood stream infection of EBSL-positive klebsiella pneumoniae, one patient had both pulmonary infection of Candida tropicalis and blood stream infection of bacillus, and one patient had pulmonary infection of Stenotrophomonas maltophilia and carbapenem-resistant Acinetobacter baumannii. |
T199 |
1268-1459 |
Sentence |
denotes |
The health condition of nine [12.0%] patients in the poor-sleep group deteriorated and required ICU care (P = 0.0151); meanwhile, none of the patients in the good-sleep group needed ICU care. |
T200 |
1460-1658 |
Sentence |
denotes |
In addition, patients in the poor-sleep group had an increased hospital stay (median, 33.0 [IQR, 23.0–47.0] days vs 25.0 [IQR, 20.5–36.5] days, P = 0.0116) compared to those in the good-sleep group. |
T201 |
1659-1787 |
Sentence |
denotes |
Table 3 Laboratory parameters on hospital admission as well as complications, treatments and outcomes of patients with COVID-19. |
T202 |
1788-1864 |
Sentence |
denotes |
Normal range Total (n = 135) Good-sleep (n = 60) Poor-sleep (n = 75) P value |
T203 |
1865-1879 |
Sentence |
denotes |
Blood routine: |
T204 |
1880-1974 |
Sentence |
denotes |
White blood count, ×109/L 3.50–9.50 5.36 (4.16–7.18) 6.06 (4.77–7.57) 5.16 (4.09–6.78) 0.1260 |
T205 |
1975-2068 |
Sentence |
denotes |
Neutrophil count, ×109/L 1.80–6.30 4.23 (2.98–5.99) 4.60 (3.30–6.61) 3.92 (2.92–5.54) 0.1700 |
T206 |
2069-2162 |
Sentence |
denotes |
Neutrophil percentage, % 40.0–75.0 78.9 (72.1–86.7) 79.7 (73.6–86.9) 76.5 (71.9–85.9) 0.1515 |
T207 |
2163-2256 |
Sentence |
denotes |
Lymphocyte count, ×109/L 1.10–3.20 0.75 (0.55–0.95) 0.72 (0.55–0.93) 0.81 (0.55–0.96) 0.5126 |
T208 |
2257-2347 |
Sentence |
denotes |
Lymphocyte percentage, % 20.0–50.0 14.5 (8.5–18.1) 11.8 (8.1–17.8) 14.8 (8.9–19.2) 0.2271 |
T209 |
2348-2446 |
Sentence |
denotes |
Platelet count, ×109/L 125–350 207.0 (153.0–258.0) 207.0 (145.0–264.5) 207.0 (154.5–247.0) 0.9358 |
T210 |
2447-2471 |
Sentence |
denotes |
Coagulation parameters†: |
T211 |
2472-2581 |
Sentence |
denotes |
Activated partial thromboplastin time, S 27.0–45.0 38.0 (34.8–42.2) 38.6 (35.4–42.9) 37.9 (34.7–41.6) 0.7342 |
T212 |
2582-2663 |
Sentence |
denotes |
Prothrombin time, S 11.0–16.0 13.5 (12.6–14.2) 13.4 (12.7–14.2) 13.5 (12.6–14.2) |
T213 |
2664-2737 |
Sentence |
denotes |
D-dimer ≥ 0.5, μg/mL, n (%) 0.0–0.5 72 (53.3) 29 (48.3) 43 (57.3) 0.2976 |
T214 |
2738-2774 |
Sentence |
denotes |
Blood biochemistry and electrolyte‡: |
T215 |
2775-2856 |
Sentence |
denotes |
Albumin, g/L 33.0–55.0 29.7 (26.8–32.6) 30.4 (27.5–34.2) 28.7 (26.1–32.0) 0.0386 |
T216 |
2857-2946 |
Sentence |
denotes |
Alanine transaminase, U/L 5–40 38.0 (24.5–58.5) 42.5 (29.0–72.5) 33.0 (23.0–54.0) 0.0424 |
T217 |
2947-3035 |
Sentence |
denotes |
Total bilirubin, μmol/L 3.0–20.0 10.7 (7.3–14.0) 11.7 (8.6–14.0) 10.1 (6.7–14.0) 0.1305 |
T218 |
3036-3132 |
Sentence |
denotes |
Blood urea nitrogen, mmol/L 2.90–8.20 4.77 (3.63–6.47) 5.52 (3.52–7.42) 4.65 (3.64–5.83) 0.1422 |
T219 |
3133-3227 |
Sentence |
denotes |
Serum creatinine, μmol/L 57.0–111.0 69.3 (58.5–85.0) 69.7 (58.7–86.3) 68.0 (57.3–82.6) 0.9991 |
T220 |
3228-3318 |
Sentence |
denotes |
Creatine kinase, U/L‡ 24–194 69.0 (47.0–130.0) 81.0 (52.0–165.0) 64.5 (40.0–105.5) 0.0288 |
T221 |
3319-3421 |
Sentence |
denotes |
Lactate dehydrogenase, U/L 109–245 305.0 (224.5–380.5) 326.0 (225.0–402.0) 277.0 (224.5–367.0) 0.1233 |
T222 |
3422-3506 |
Sentence |
denotes |
Glucose, mmol/L 3.90–6.10 6.40 (5.53–8.63) 6.37 (5.77–9.78) 6.55 (5.47–8.20) 0.3565 |
T223 |
3507-3604 |
Sentence |
denotes |
Total carbon dioxide, mmol/L 20.0–29.0 24.1 (21.6–28.0) 23.6 (21.7–27.6) 24.6 (21.6–28.4) 0.3503 |
T224 |
3605-3699 |
Sentence |
denotes |
Sodium, mmol/L 137.0–147.0 138.2 (135.9–140.3) 137.8 (135.3–140.1) 138.5 (136.5–140.4) 0.2621 |
T225 |
3700-3786 |
Sentence |
denotes |
Potassium, mmol/L 3.50–5.30 3.75 (3.41–4.11) 3.82 (3.50–4.17) 3.65 (3.39–4.07) 0.1872 |
T226 |
3787-3807 |
Sentence |
denotes |
Cardiac biomarkers§: |
T227 |
3808-3866 |
Sentence |
denotes |
Creatine kinase-MB ≥ 6.6, ng/mL < 6.6 0 (0) 0 (0) 0 (0) – |
T228 |
3867-3952 |
Sentence |
denotes |
Hypersensitive cardiac troponin I ≥ 26.2, ng/L < 26.2 7 (5.2) 5 (8.3) 2 (2.7) 0.2779 |
T229 |
3953-3966 |
Sentence |
denotes |
Complications |
T230 |
3967-4030 |
Sentence |
denotes |
Acute liver dysfunction – 84 (62.2) 37 (61.7) 47 (62.7) 0.9052 |
T231 |
4031-4085 |
Sentence |
denotes |
Hyperglycaemia – 64 (47.4) 31 (51.7) 33 (44.0) 0.3754 |
T232 |
4086-4147 |
Sentence |
denotes |
Hospital-acquired infection – 8 (5.9) 1 (1.7) 7 (9.3) 0.1316 |
T233 |
4148-4199 |
Sentence |
denotes |
Acute kidney injury – 3 (2.2) 0 (0) 3 (4.0) 0.3275 |
T234 |
4200-4254 |
Sentence |
denotes |
Acute cardiac injury – 3 (2.2) 1 (1.7) 2 (2.7) 0.8447 |
T235 |
4255-4265 |
Sentence |
denotes |
Treatment: |
T236 |
4266-4281 |
Sentence |
denotes |
Oxygen therapy |
T237 |
4282-4336 |
Sentence |
denotes |
Nasal cannula – 102 (75.6) 48 (80.0) 64 (85.3) 0.4128 |
T238 |
4337-4388 |
Sentence |
denotes |
Oxygen mask – 32 (23.7) 16 (26.7) 16 (21.3) 0.4690 |
T239 |
4389-4437 |
Sentence |
denotes |
Without oxygen – 3 (2.2) 1 (1.7) 2 (2.7) 0.8447 |
T240 |
4438-4496 |
Sentence |
denotes |
Antiviral therapy – 132 (97.8) 59 (98.3) 73 (97.3) 0.6953 |
T241 |
4497-4549 |
Sentence |
denotes |
Antibiotics – 105 (79.5) 44 (73.3) 61 (81.3) 0.2666 |
T242 |
4550-4614 |
Sentence |
denotes |
Immunoregulatory therapy – 79 (58.5) 37 (61.7) 42 (56.0) 0.5067 |
T243 |
4615-4670 |
Sentence |
denotes |
Corticosteroids – 74 (54.8) 32 (53.3) 42 (56.0) 0.7570 |
T244 |
4671-4725 |
Sentence |
denotes |
Immunoglobulin – 39 (28.9) 21 (35.0) 18 (24.0) 0.1612 |
T245 |
4726-4785 |
Sentence |
denotes |
Vasoconstrictive agents – 13 (9.6) 6 (10.0) 7 (9.3) 0.8962 |
T246 |
4786-4835 |
Sentence |
denotes |
Requring ICU care – 9 (6.7) 0 (0) 9 (12.0) 0.0151 |
T247 |
4836-4942 |
Sentence |
denotes |
Total length of hospital stay, median (IQR), d – 29.0 (21.0–45.0) 25.0 (20.5–36.5) 33.0 (23.0–47.0) 0.0116 |
T248 |
4943-5000 |
Sentence |
denotes |
Values are median (IQR [range]) or numbers (percentages). |
T249 |
5001-5127 |
Sentence |
denotes |
Abbreviations: IQR, interquartile range; n, number. aP values indicate differences between good-sleep and poor-sleep patients. |
T250 |
5128-5178 |
Sentence |
denotes |
P < 0.05 was considered statistically significant. |
T251 |
5179-5493 |
Sentence |
denotes |
†Data were missing for the measurement of activated partial thromboplastin time, prothrombin time, or D-dimer in five patients (8.3%), five patients (8.3%), and 10 patients (16.6%) in the good-sleep group, and six patients (8.0%), six patients (8.0%), and 10 patients (13.3%) in the poor-sleep group, respectively. |
T252 |
5494-5639 |
Sentence |
denotes |
‡Data regarding creatine kinase were missing for seven patients (11.7%) in the good-sleep group, and 11 patients (14.7%) in the poor-sleep group. |